Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Université de Montréal

$135,000.00

A novel putative Bmi1-E4F1-Map1s complex regulates self-renewal of hematopoietic stem/progenitor cells

FY 2009-10

Summary
Hematopoietic stem cells (HSCs) have the unique ability to give rise to all blood cell types and are thus indispensable for hematpoietic system development, homeostasis and repair. Normal HSC function critically depends on pronounced self-renewal capabilities, which make HSCs the preferred cell-type for cell transplantation therapy, one of the most effective treatments against aggressive blood diseases. Contrariwise, the long life span of HSCs, combined with their distinct proliferative potential, increases the risk to acquire DNA-mutations, which could possibly transform HSCs into malignant leukemic stem cells (LSCs), stem cell like cancerous cells implicated in blood cancer initiation and progression. Therefore, understanding the molecular mechanism underlying self-renewal in HSC and LSC is central for the development of novel stem cell therapies as well as anti-cancer drugs. In this respect, we propose to study a novel putative Bmi1-E4F1-Map1s protein complex, implicated in self-renewal of HSCs and LCSs. We believe that this complex determines the cellular activity of the oncogene Bmi1, which is known to be necessary for the maintenance of both HSCs and LSCs. E4F1 and Map1s would antagonize the proliferative effects of Bmi1, whereas Bmi1 overcomes the inhibition of E4F1/Map1s by inducing their intracellular degradation. Hence, the dynamics of the Bmi1-E4F1-Map1s protein interactions likely determines the proliferative rates of HSCs and LSCs. My research will focus at proofing this hypothesis genetically in various combined mouse model systems. In parallel, I intend to validate and study the Bmi1-E4F1-Map1s complex biochemically in HSCs/LSCs. In summary, the results obtained from these experiments will shed light on the mechanism(s) of self-renewal in normal and malignant stem cells. Subsequently, those data would also be beneficial for the development of novel therapies to fight blood cancers.
Program
CIHR Fellowship
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
193043
Name
Grote David
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
A novel putative Bmi1-E4F1-Map1s complex regulates self-renewal of hematopoietic stem/progenitor cells
Programtype2
Fellowship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Affinity Purification; Bmi1; Cancer Stem Cells; Cell-Cycle Regulation; E4f1; Live Imaging; Map1s; Mouse Models; Stem Cells; Ubiquitination Assays
Abstract
Hematopoietic stem cells (HSCs) have the unique ability to give rise to all blood cell types and are thus indispensable for hematpoietic system development, homeostasis and repair. Normal HSC function critically depends on pronounced self-renewal capabilities, which make HSCs the preferred cell-type for cell transplantation therapy, one of the most effective treatments against aggressive blood diseases. Contrariwise, the long life span of HSCs, combined with their distinct proliferative potential, increases the risk to acquire DNA-mutations, which could possibly transform HSCs into malignant leukemic stem cells (LSCs), stem cell like cancerous cells implicated in blood cancer initiation and progression. Therefore, understanding the molecular mechanism underlying self-renewal in HSC and LSC is central for the development of novel stem cell therapies as well as anti-cancer drugs. In this respect, we propose to study a novel putative Bmi1-E4F1-Map1s protein complex, implicated in self-renewal of HSCs and LCSs. We believe that this complex determines the cellular activity of the oncogene Bmi1, which is known to be necessary for the maintenance of both HSCs and LSCs. E4F1 and Map1s would antagonize the proliferative effects of Bmi1, whereas Bmi1 overcomes the inhibition of E4F1/Map1s by inducing their intracellular degradation. Hence, the dynamics of the Bmi1-E4F1-Map1s protein interactions likely determines the proliferative rates of HSCs and LSCs. My research will focus at proofing this hypothesis genetically in various combined mouse model systems. In parallel, I intend to validate and study the Bmi1-E4F1-Map1s complex biochemically in HSCs/LSCs. In summary, the results obtained from these experiments will shed light on the mechanism(s) of self-renewal in normal and malignant stem cells. Subsequently, those data would also be beneficial for the development of novel therapies to fight blood cancers.
Competitiondate
200910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Grote, David
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~
Université de Montréal - $135,000 Grant (2009-10) | Canada Spends